+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Dilated Cardiomyopathy Therapeutics - Global Market Trajectory & Analytics

  • ID: 5140340
  • Report
  • September 2020
  • Region: Global
  • 137 pages
  • Global Industry Analysts, Inc
Global Dilated Cardiomyopathy Therapeutics Market to Reach $411.6 Million by 2027

Amid the COVID-19 crisis, the global market for Dilated Cardiomyopathy Therapeutics estimated at US$304.5 Million in the year 2020, is projected to reach a revised size of US$411.6 Million by 2027, growing at a CAGR of 4.4% over the analysis period 2020-2027. Aldosterone Antagonists, one of the segments analyzed in the report, is projected to record a 3.7% CAGR and reach US$40.8 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Angiotensin-Converting Enzyme (ACE) Inhibitors segment is readjusted to a revised 3.4% CAGR for the next 7-year period.

The U. S. Market is Estimated at $89.7 Million, While China is Forecast to Grow at 4.2% CAGR

The Dilated Cardiomyopathy Therapeutics market in the U. S. is estimated at US$89.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$72.9 Million by the year 2027 trailing a CAGR of 4.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.2% and 3.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Angiotensin II Receptor Blockers (ARBs) Segment to Record 5% CAGR

In the global Angiotensin II Receptor Blockers (ARBs) segment, USA, Canada, Japan, China and Europe will drive the 5.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$112.5 Million in the year 2020 will reach a projected size of US$160.3 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$45.8 Million by the year 2027. We bring years of research experience to this 6th edition of our report. The 137-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others:
  • Array BioPharma, Inc.
  • AstraZeneca PLC
  • GlaxoSmithKline PLC
  • Janssen Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Vericel Corporation
Note: Product cover images may vary from those shown
I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
  • Global Competitor Market Shares
  • Dilated Cardiomyopathy Therapeutics Competitor Market Share Scenario Worldwide (in %): 2019 & 2025
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: Dilated Cardiomyopathy Therapeutics Global Market Estimates and Forecasts in US$ Thousand by Region/Country: 2020-2027
  • TABLE 2: Dilated Cardiomyopathy Therapeutics Global Retrospective Market Scenario in US$ Thousand by Region/Country: 2012-2019
  • TABLE 3: Dilated Cardiomyopathy Therapeutics Market Share Shift across Key Geographies Worldwide: 2012 VS 2020 VS 2027
  • TABLE 4: Aldosterone Antagonists (Drug Class) World Market by Region/Country in US$ Thousand: 2020 to 2027
  • TABLE 5: Aldosterone Antagonists (Drug Class) Historic Market Analysis by Region/Country in US$ Thousand: 2012 to 2019
  • TABLE 6: Aldosterone Antagonists (Drug Class) Market Share Breakdown of Worldwide Sales by Region/Country: 2012 VS 2020 VS 2027
  • TABLE 7: Angiotensin-Converting Enzyme (ACE) Inhibitors (Drug Class) Potential Growth Markets Worldwide in US$ Thousand: 2020 to 2027
  • TABLE 8: Angiotensin-Converting Enzyme (ACE) Inhibitors (Drug Class) Historic Market Perspective by Region/Country in US$ Thousand: 2012 to 2019
  • TABLE 9: Angiotensin-Converting Enzyme (ACE) Inhibitors (Drug Class) Market Sales Breakdown by Region/Country in Percentage: 2012 VS 2020 VS 2027
  • TABLE 10: Angiotensin II Receptor Blockers (ARBs) (Drug Class) Geographic Market Spread Worldwide in US$ Thousand: 2020 to 2027
  • TABLE 11: Angiotensin II Receptor Blockers (ARBs) (Drug Class) Region Wise Breakdown of Global Historic Demand in US$ Thousand: 2012 to 2019
  • TABLE 12: Angiotensin II Receptor Blockers (ARBs) (Drug Class) Market Share Distribution in Percentage by Region/Country: 2012 VS 2020 VS 2027
  • TABLE 13: Beta-Blockers (Drug Class) World Market Estimates and Forecasts by Region/Country in US$ Thousand: 2020 to 2027
  • TABLE 14: Beta-Blockers (Drug Class) Market Historic Review by Region/Country in US$ Thousand: 2012 to 2019
  • TABLE 15: Beta-Blockers (Drug Class) Market Share Breakdown by Region/Country: 2012 VS 2020 VS 2027
III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES
  • Market Facts & Figures
  • US Dilated Cardiomyopathy Therapeutics Market Share (in %) by Company: 2019 & 2025
  • Market Analytics
  • TABLE 16: United States Dilated Cardiomyopathy Therapeutics Market Estimates and Projections in US$ Thousand by Drug Class: 2020 to 2027
  • TABLE 17: Dilated Cardiomyopathy Therapeutics Market in the United States by Drug Class: A Historic Review in US$ Thousand for 2012-2019
  • TABLE 18: United States Dilated Cardiomyopathy Therapeutics Market Share Breakdown by Drug Class: 2012 VS 2020 VS 2027
CANADA
  • TABLE 19: Canadian Dilated Cardiomyopathy Therapeutics Market Estimates and Forecasts in US$ Thousand by Drug Class: 2020 to 2027
  • TABLE 20: Canadian Dilated Cardiomyopathy Therapeutics Historic Market Review by Drug Class in US$ Thousand: 2012-2019
  • TABLE 21: Dilated Cardiomyopathy Therapeutics Market in Canada: Percentage Share Breakdown of Sales by Drug Class for 2012, 2020, and 2027
JAPAN
  • TABLE 22: Japanese Market for Dilated Cardiomyopathy Therapeutics:Annual Sales Estimates and Projections in US$ Thousand by Drug Classfor the Period 2020-2027
  • TABLE 23: Dilated Cardiomyopathy Therapeutics Market in Japan: Historic Sales Analysis in US$ Thousand by Drug Class for the Period 2012-2019
  • TABLE 24: Japanese Dilated Cardiomyopathy Therapeutics Market Share Analysis by Drug Class: 2012 VS 2020 VS 2027
CHINA
  • TABLE 25: Chinese Dilated Cardiomyopathy Therapeutics Market Growth Prospects in US$ Thousand by Drug Class for the Period 2020-2027
  • TABLE 26: Dilated Cardiomyopathy Therapeutics Historic Market Analysis in China in US$ Thousand by Drug Class: 2012-2019
  • TABLE 27: Chinese Dilated Cardiomyopathy Therapeutics Market by Drug Class: Percentage Breakdown of Sales for 2012, 2020, and 2027
EUROPE
  • Market Facts & Figures
  • European Dilated Cardiomyopathy Therapeutics Market: Competitor Market ShareScenario (in %) for 2019 & 2025
  • Market Analytics
  • TABLE 28: European Dilated Cardiomyopathy Therapeutics Market Demand Scenario in US$ Thousand by Region/Country: 2020-2027
  • TABLE 29: Dilated Cardiomyopathy Therapeutics Market in Europe: A Historic Market Perspective in US$ Thousand by Region/Country for the Period 2012-2019
  • TABLE 30: European Dilated Cardiomyopathy Therapeutics Market Share Shift by Region/Country: 2012 VS 2020 VS 2027
  • TABLE 31: European Dilated Cardiomyopathy Therapeutics Market Estimates and Forecasts in US$ Thousand by Drug Class: 2020-2027
  • TABLE 32: Dilated Cardiomyopathy Therapeutics Market in Europe in US$ Thousand by Drug Class: A Historic Review for the Period 2012-2019
  • TABLE 33: European Dilated Cardiomyopathy Therapeutics Market Share Breakdown by Drug Class: 2012 VS 2020 VS 2027
FRANCE
  • TABLE 34: Dilated Cardiomyopathy Therapeutics Market in France by Drug Class: Estimates and Projections in US$ Thousand for the Period 2020-2027
  • TABLE 35: French Dilated Cardiomyopathy Therapeutics Historic Market Scenario in US$ Thousand by Drug Class: 2012-2019
  • TABLE 36: French Dilated Cardiomyopathy Therapeutics Market Share Analysis by Drug Class: 2012 VS 2020 VS 2027
GERMANY
  • TABLE 37: Dilated Cardiomyopathy Therapeutics Market in Germany: Recent Past,Current and Future Analysis in US$ Thousand by Drug Classfor the Period 2020-2027
  • TABLE 38: German Dilated Cardiomyopathy Therapeutics Historic Market Analysis in US$ Thousand by Drug Class: 2012-2019
  • TABLE 39: German Dilated Cardiomyopathy Therapeutics Market Share Breakdown by Drug Class: 2012 VS 2020 VS 2027
ITALY
  • TABLE 40: Italian Dilated Cardiomyopathy Therapeutics Market Growth Prospects in US$ Thousand by Drug Class for the Period 2020-2027
  • TABLE 41: Dilated Cardiomyopathy Therapeutics Historic Market Analysis in Italy in US$ Thousand by Drug Class: 2012-2019
  • TABLE 42: Italian Dilated Cardiomyopathy Therapeutics Market by Drug Class: Percentage Breakdown of Sales for 2012, 2020, and 2027
UNITED KINGDOM
  • TABLE 43: United Kingdom Market for Dilated Cardiomyopathy Therapeutics: Annual Sales Estimates and Projections in US$ Thousand by Drug Class for the Period 2020-2027
  • TABLE 44: Dilated Cardiomyopathy Therapeutics Market in the United Kingdom: Historic Sales Analysis in US$ Thousand by Drug Class for the Period 2012-2019
  • TABLE 45: United Kingdom Dilated Cardiomyopathy Therapeutics Market Share Analysis by Drug Class: 2012 VS 2020 VS 2027
REST OF EUROPE
  • TABLE 46: Rest of Europe Dilated Cardiomyopathy Therapeutics Market Estimates and Forecasts in US$ Thousand by Drug Class: 2020-2027
  • TABLE 47: Dilated Cardiomyopathy Therapeutics Market in Rest of Europe in US$ Thousand by Drug Class: A Historic Review for the Period 2012-2019
  • TABLE 48: Rest of Europe Dilated Cardiomyopathy Therapeutics Market Share Breakdown by Drug Class: 2012 VS 2020 VS 2027
ASIA-PACIFIC
  • TABLE 49: Dilated Cardiomyopathy Therapeutics Market in Asia-Pacific by Drug Class: Estimates and Projections in US$ Thousand for the Period 2020-2027
  • TABLE 50: Asia-Pacific Dilated Cardiomyopathy Therapeutics Historic Market Scenario in US$ Thousand by Drug Class: 2012-2019
  • TABLE 51: Asia-Pacific Dilated Cardiomyopathy Therapeutics Market Share Analysis by Drug Class: 2012 VS 2020 VS 2027
REST OF WORLD
  • TABLE 52: Rest of World Dilated Cardiomyopathy Therapeutics Market Estimates and Forecasts in US$ Thousand by Drug Class: 2020 to 2027
  • TABLE 53: Rest of World Dilated Cardiomyopathy Therapeutics Historic Market Review by Drug Class in US$ Thousand: 2012-2019
  • TABLE 54: Dilated Cardiomyopathy Therapeutics Market in Rest of World: Percentage Share Breakdown of Sales by Drug Class for 2012, 2020, and 2027
IV. COMPETITION
  • Total Companies Profiled: 47
Note: Product cover images may vary from those shown
Adroll
adroll